Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

BACKGROUND: This study explored the efficacy of lenalidomide plus rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) including cases of secondary central nervous system (CNS) involvement and transformed follicular lymphoma (FL) in real-world context because of a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Manag Res
Asıl Yazarlar: Lee, Yong-Pyo, Hong, Jung Yong, Yoon, Sang Eun, Cho, Junhun, Shim, Joon-Ho, Bang, Yeonghak, Kim, Won Seog, Kim, Seok Jin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2021
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168964/
https://ncbi.nlm.nih.gov/pubmed/34093038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S309092
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller